Nizatidine occurs as histamine H₂-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade list Tazac & Axid.

Clinical use
Independent article: H2-receptor antagonist

Certain preparations of nizatadine come at present available over the counter in various countries including the United States.

History and development
Nizatidine was developed by Eli Lilly, and was 1st marketed around 1987. These are considered to exist as equipotent using ranitidine and differs by the substitution of the thiazole-ring in place of the furan-ring in zantac.

Nazitidine proved to become a endure recently histamine H_Two-receptor antagonists introduced before a advent of proton pump inhibitors.